Recombinant activated factor VII in refractory gastrointestinal haemorrhage of unknown aetiology

Bratislava Medical Journal

Volumn 109, Issue 10, 2008, Pages 438-440

  Matic, I ^a   Titlic, Marina ^b   Lucic, I ^a   Mirkovic, I ^a   Jurjevic, M ^a  

^a DR JOSIP BEN EVI GENERAL HOSPITAL   (Croatia)

^b UNIVERSITY HOSPITAL SPLIT   (Croatia)

Author keywords

Erythrocyte transfusion; Gastrointestinal haemorrhage; Haemostatics; Laparotomy

Indexed keywords

BLOOD CLOTTING FACTOR 7A;

ACUTE DISEASE; ADULT; ARTICLE; CASE REPORT; GASTROINTESTINAL HEMORRHAGE; HUMAN; MALE; POSTOPERATIVE HEMORRHAGE; RECTUM;

ACUTE DISEASE; ADULT; FACTOR VIIA; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; POSTOPERATIVE HEMORRHAGE; RECTUM;

EID: 62549111289     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Blatchford O, Davidson LA, Murray WR et al. Acute upper gastrointestinal haemorrhage in west of Scotland: case ascertainment study. Brit Med J 1997; 315: 510-514.
2. Vilstrup H, Markiewicz M, Biesma D et al. Recombinant activated factor VII in an unselected series of cases with upper gastrointestinal bleeding. Thromb Res 2006; (in press).
3. Appleyard MN, Swain CP. Endoscopic difficulties in the diagnosis of upper gastrointestinal bleeding. World J Gastroenterol 2001; 7: 308-312.
4. British Society of Gastroenterology Endoscopy Committee. Nonvariceal upper gastrointestinal haemorrhage: guidelines. Gut 2002; 51 (Suppl 4); iv1-6.
5. Foutch PG. Angiodysplasia of the gastrointestinal tract. Amer J Gastroenterol 1993; 88: 807-818.
6. Dallal HJ, Palmer KR. ABC of the upper gastrointestinal tract: Upper gastrointestinal haemorrhage. Brit Med J 2001; 323: 1115-1117.
7. Poon MC, D'Oiron R, Von Depka M et al. Prophylactic and therapeutic recombinant factor VIIa administration to patients with Glanzmann's thrombasthenia: results of an international survey. J Thromb Haemost 2004; 2: 1096-1103.
8. Friederich PW, Henny CP, Messelink EJ et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet 2003; 361: 201-205.
9. Gala B, Quintela J, Aguirrezabalaga J et al. Benefits of recombinant activated factor VII in complicated liver transplantation. Transplant Proc 2005; 37: 3919-3921.
10. Boffard KD, Riou B, Warren B et al. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials. J Trauma 2005; 59: 8-18.
11. Udvardy M, Telek B, Mezey G et al. Successful control of massive coumarol-induced acute upper gastrointestinal bleeding and correction of prothrombin time by recombinant active factor VII (Eptacog-alpha, NovoSeven) in a patient with a prosthetic aortic valve and two malignancies (chronic lymphoid leukaemia and lung cancer). Blood Coagul Fibrinolysis 2004; 15: 265-267.
12. Bosch J, Thabut D, Bendtsen F et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology 2004; 127: 1123-1130.
13. Kurekci AE, Atay AA, Okutan V et al. Recombinant activated factor VII for severe gastrointestinal bleeding after chemotherapy in an infant with acute megakaryoblastic leukemia. Blood Coagul Fibrinolysis 2005; 16: 145-147.
14. Tonkic A, Jukic I, Titlic M et al. Successful treatment of massive acute upper gastrointestinal bleeding in liver failure with activated recombinant factor VII (NovoSeven): a case report. Blood Coagul Fibrinolysis 2005; 16: 385-387.
15. Roberts HR, Monroe DM III, Hoffman M. Safety profile of recombinant factor VIIa. Semin Hematol 2004; 41 (Suppl 1): 101-108.
16. Eikelboom JW, Bird R, Blythe D et al. Recombinant activated factor VII for the treatment of life-threatening haemorrhage. Blood Coagul Fibrinolysis 2003; 14: 713-717.
17. Hoffman M, Monroe DM 3rd, Roberts HR. Activated factor VII activates factors IX and X on the surface of activated platelets: thoughts on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis 1998; 9 (Suppl 1): S61-65.